Royal Bank Of Canada Clene Inc. Transaction History

Royal Bank Of Canada

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.31 - $0.44 $116 - $165	376 Added 318.64%	494 $0
Q1 2024 Nov 05, 2024	SELL	$0.28 - $0.53 $105 - $199	-376 Reduced 76.11%	118 $0
Q1 2024 May 15, 2024	SELL	$0.28 - $0.53 $125 - $237	-449 Reduced 79.19%	118 $0
Q4 2023 Feb 14, 2024	BUY	$0.26 - $0.55 $113 - $240	438 Added 339.53%	567 $0
Q3 2023 Nov 14, 2023	SELL	$0.46 - $0.87 $214 - $406	-467 Reduced 78.36%	129 $0
Q2 2023 Aug 14, 2023	BUY	$0.78 - $1.22 $464 - $727	596 New	596 $0
Q3 2022 Nov 14, 2022	BUY	$0.33 - $73.0 $17,165 - $3.8 Million	52,017 New	52,017 $146,000
Q2 2022 Aug 15, 2022	SELL	$2.1 - $4.12 $2,646 - $5,191	-1,260 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.42 - $4.42 $7,390 - $13,498	-3,054 Reduced 70.79%	1,260 $5,000
Q4 2021 Feb 14, 2022	BUY	$3.95 - $7.53 $10,514 - $20,044	2,662 Added 161.14%	4,314 $17,000
Q3 2021 Nov 15, 2021	BUY	$6.83 - $13.58 $587 - $1,167	86 Added 5.49%	1,652 $11,000
Q2 2021 Aug 16, 2021	BUY	$6.98 - $13.33 $10,930 - $20,874	1,566 New	1,566 $18,000

230K

25K

Ticker CLNN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,502,000
Market Cap $273M
Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.